Dendreon is getting tired of soldiering on alone. As Bloomberg reports, the Seattle-based company is casting about for buyers as its prostate cancer treatment Provenge continues to lag--and Dendreon's stock lags along with it.
The EU on Friday recommended approval of Actelion's Opsumit, following FDA approval the week before, and by today the takeover talk was in full swing. With regulators giving thumbs up to a drug projected to be a blockbuster, analysts say any number of companies may want to do a deal and add the assured revenue to their own top lines.
ICU Medical is out of the running for a buyout, Bloomberg reports, giving up on a protracted process just as the company's founder and CEO steps down.
Drugmakers long ago went global, and now drug wholesalers see the need to follow the same strategy. Months after AmerisourceBergen hooked up with Walgreen's and Alliance Boots in Europe, McKesson has struck a $5.4 billion deal to buy struggling German wholesaler Celesio.
Looks like $3 billion-plus may have been a little too much to ask for Aptalis Pharma. After exploring a sale of the specialty drugmaker and finding no one to take the bait, private equity firm TPG has hired two banks for an IPO, Reuters sources say.
So is Roche going to do some rare disease deals or not? Rumors of a possible buyout of Alexion and BioMarin--alternatively dissed and touted--helped make this one of the big questions for deal watchers. Roche CEO Severin Schwan's answer can now be summarized in one word: Maybe.
Reckitt Benckiser has said the time to weigh options for its pharmaceuticals unit would come after its flagship drug, Suboxone, fell victim to generic competition. That time is now. The British consumer goods group says it's reviewing options for its pharma business, including a possible sale that could grab upwards of $3.2 billion.
U.K. contractor DrugDev has purchased software provider CFS Clinical with plans to merge the company's trial management program with its own investigator network.
Germany's Aenova has sealed a deal for contract development and manufacturing outfit Haupt Pharma, a buyout that expands its capabilities and global reach.
Pennsylvania contractor Clinlogix has bought Germany's ikfe CRO, looking to expand its presence in Europe's market for clinical development.